Current Study of Medicinal Chemistry for Treating Spinal Tuberculosis

Area of Science:

• Infectious Diseases
• Orthopedics
• Microbiology

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a leading global cause of death and the most common infectious disease.
• Spinal tuberculosis (PSTBI) is the most frequent type of extrapulmonary TB, representing 1-3% of all TB cases and 50% of musculoskeletal infections.
• Drug resistance in PSTBI poses a significant global challenge, leading to high disability and treatment difficulties.

Purpose of the Study:

• To review current understanding of medicine usage in spinal tuberculosis.
• To explore novel and extensive treatment strategies for spinal tuberculosis.
• To address the challenges posed by drug-resistant spinal tuberculosis.

Main Methods:

• Literature review of current studies on spinal tuberculosis.
• Analysis of existing data on medicine usage and treatment outcomes.
• Identification of emerging research trends and therapeutic explorations.

Main Results:

• Spinal tuberculosis remains a difficult-to-treat condition with a high disability rate.
• Drug resistance is a major complicating factor in managing spinal tuberculosis.
• Current treatment approaches require further innovation to overcome resistance and improve outcomes.

Conclusions:

• Effective management of spinal tuberculosis necessitates a deeper understanding of drug resistance mechanisms.
• Further research into novel therapeutic agents and strategies is crucial.
• Addressing the global challenge of spinal tuberculosis requires collaborative efforts from researchers and clinicians.